Detecting thyroid cancer early and avoiding unnecessary surgery is the potential promise of a new cancer diagnostic test, known as the Afirma® gene expression classifier test, developed by South San Francisco company, Veracyte.

 NEJM reports trial of Veracyte thyroid cancer diagnostic test, is it worth $4,200?

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase access to all Premium Content. Current subscription rate is $369 for 3 months access (does not auto renew), $598 for 6 months access (does not auto renew) and $997 for 12 months access (does not auto renew). Rates may change without notice and are non-refundable. Please read the Terms of Use before purchasing and if in communications our Guidance to PR Professionals contained within it.